Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SECIRA-UM: ipilimumab plus radiofrequency ablation in unresectable uveal melanoma liver metastases
2011-004200-38Phase 2Active
- Sponsor
- Netherlands Cancer Institute
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab in intraocular melanoma, sponsored by Netherlands Cancer Institute. Primary endpoint: Safety and efficacy of ipilimumab plus radiofrequency ablation. Started Dec 2011; status: active.
02
Drugs
ipilimumab
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2011-004200-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004200-38.